Queen Elizabeth II, Health Sciences Centre

The trials here

What the 31 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia3 trials
• Atrial fibrillation3 trials
• Childhood cancers3 trials
• Multiple myeloma3 trials
• Acute lymphoblastic leukaemia2 trials
• Aortic stenosis2 trials
• Coronary artery disease2 trials
• Follicular lymphoma2 trials
• Lung cancer2 trials
• Asthma1 trial
• Chronic kidney disease1 trial
• Chronic lymphocytic leukaemia1 trial
• and 13 more

Phase

• Phase 314 trials
• Phase 1/22 trials
• Phase 22 trials
• Phase 42 trials
• Phase 2/31 trial

Status

• Active, not recruiting13 trials
• Recruiting10 trials
• Completed7 trials
• Terminated1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Amgen2 trials
• Incyte Corporation2 trials
• Ottawa Hospital Research Institute2 trials
• University Health Network, Toronto2 trials
• and 20 more

Running trials

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR)

  NCT06930781· Oticon Medical· Source

  Contact: Dr David Morris

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Allogene Therapeutics· Source

  Contact: Mahmoud Elsawy, MD (principal investigator)

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Evolut™ EXPAND TAVR II Pivotal Trial

  NCT05149755· Medtronic Cardiovascular· Source

• Active, not recruiting

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Amgen· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Incyte Corporation· Source

• Recruiting

  Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

  NCT05100420· Montreal Heart Institute· Source

  Contact: David Lee (principal investigator)

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· University of British Columbia· Source

  Contact: Osama ElKhateeb, MD

• Active, not recruiting

  ATG Plus PTCy vs ATG for CGVHD Prophylaxis

  NCT04202835· Phase 2· McMaster University· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Active, not recruiting

  First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

  NCT04067336· Phase 1/2· Kura Oncology, Inc.· Source

• Active, not recruiting

  Critical Care Outcomes of Hematologic Oncology Patients

  NCT03449953· Mount Sinai Hospital, Canada· Source

• Active, not recruiting

  Multiple Myeloma Molecular Monitoring Study

  NCT03421132· Horizon Health Network· Source

• Recruiting

  Canadian Network for Autoimmune Liver Disease

  NCT03569826· University Health Network, Toronto· Source

  Contact: Surain Roberts, AB

• Active, not recruiting

  A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

  NCT02773030· Phase 1/2· Celgene· Source

• Recruiting

  Canadian Fabry Disease Initiative (CFDI) National Registry

  NCT00455104· Canadian Fabry Research Consortium· Source

  Contact: Michael L West, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease2 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Chronic kidney disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fabry disease1 recruiting
• Hearing loss1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  A Web-based Peer Navigation Program for Men With Prostate Cancer

  NCT05041504· University Health Network, Toronto· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

  NCT04485195· Phase 4· Ottawa Hospital Research Institute· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· Phase 3· Takeda· Source

• Completed

  Undiagnosed COPD and Asthma Population Study (UCAP)

  NCT03148210· Ottawa Hospital Research Institute· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source